

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 09/744,804 |
| Filing Date | January 30, 2001 |
| First Named Inventor | EISENBACH et al. |
| Group Art Unit | 1642 |
| Examiner Name | M. Yu |
| Attorney Docket Number | EISENBACH=3 |

02 SEP -6 PM 2:45

RECEIVED
TECH CENTER 1600/2900**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-----------------------|--------------------------|--|-----------------------|
| my | AM | NSEYO et al., Immunotherapy of Bladder Cancer, Seminars in Surgical Oncology, 13:342-349 (1997) | RECEIVED |
| | AN | URBAN et al., Tumor Antigens, Annu. Rev. Immunol., 10:617-44 (1992) | SEP 10 2002 |
| | AO | ACRES et al., Vaccinia Virus MUC1 Immunization of Mice: Immune Response and Protection Against the Growth of Murine Tumors Bearing the MUC1 Antigen, Journal of Immunotherapy, 14:136-143 (1993) | TECH CENTER 1600/2900 |
| | AP | GJERTSEN et al., Ex vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of A Phase I/II Study, Int. J. Cancer, 65:450-453 (1996) | |
| | AQ | MURPHY et al., Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed With HLA-A0201-Specific Peptides from Prostate-Specific Membrane Antigen, The Prostate, 29:371-380 (1996) | |
| | AR | XUE et al., Induction of Human Cytotoxic T Lymphocytes Specific for Prostate-Specific Antigen, The Prostate, 30:73-78 (1997) | |
| | AS | CORREALE et al., In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen, Journal of the National Cancer Institute, 89(4):293-300 (1997) | |
| | AT | TJOA et al., Presentation of Prostate Tumor Antigens by Dendritic Cells Stimulates T-Cell Proliferation and Cytotoxicity, The Prostate, 28:65-69 (1996) | |
| | AU | BARND et al., Specific, Major Histocompatibility Complex-Unrestricted Recognition of Tumor-Associated Mucins by Human Cytotoxic T Cells, Proc. Natl. Acad. Sci. USA, 86:7159-7163 (1989) | |
| | AV | AGRAWAL et al., In Vitro Induction of MUC-1 Peptide-Specific Type 1 T Lymphocyte and Cytotoxic T Lymphocyte Responses from Healthy Multiparous Donors, The Journal of Immunology, 157:2089-2095 (1996) | |
| | AW | COUTO et al., Anti-BA46 Monoclonal Antibody Mc3: Humanization Using A Novel Positional Consensus and In Vivo and In Vitro Characterization, Cancer Research, 55:1717-1722 (1995) | |
| | AX | Domenech et al., In Vito Studies of MHC-Restricted Recognition of A Peptide From the MUC1 Tandem Repeat Domain by CTL, FASEB J., 9:A1023 | |
| ✓ | AY | APOSTOLOPOULOS et al., Induction of HLA-A2-Restricted CTLs to the Mucin 1 Human Breast Cancer Antigen, The Journal of Immunology, 159:5211-5218 (1997) | |

Examiner
Signature

Mishra

Date
Considered

10-08-02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.